×
Please click
here
if you are not redirected within a few seconds.
All
News
Maps
Images
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Autolus Therapeutics (AUTL) Scheduled to Post Earnings on Tuesday
Defense World
Autolus Therapeutics (NASDAQ:AUTL – Get Free Report) is scheduled to post its quarterly earnings results before the market opens on Tuesday,...
22 hours ago
Collaboration will expand opportunities beyond autologous cell therapies
biopharma-reporter.com
A collaboration to expand autologous CAR-T programs into trials for multiple cancers in a cost-efficient way, has been formed by BioNTech SE...
3 months ago
Autolus Therapeutics' CAR-T Cell Manufacturing Facility, Stevenage, UK
Pharmaceutical Technology
UK-based biotechnology company Autolus Therapeutics is building a facility, named The Nucleus, in Stevenage, UK, for the manufacturing of...
9 months ago
Autolus Therapeutics (AUTL) to Release Quarterly Earnings on Tuesday
MarketBeat
Autolus Therapeutics (NASDAQ:AUTL) will be releasing earnings before the market opens on Tuesday, May 14, Zacks reports.
5 days ago
Recent 9.9% pullback isn't enough to hurt long-term Autolus Therapeutics (NASDAQ:AUTL) shareholders, they're still up 165% over 1 year
Simply Wall Street
Autolus Therapeutics plc ( NASDAQ:AUTL ) shareholders might be concerned after seeing the share price drop 23% in the...
3 weeks ago
BioNTech agrees collaboration to accelerate CAR-T therapies
European Pharmaceutical Review
BioNTech SE and Autolus' collaboration supports a shared goal of advancing CAR-T therapies towards potential market authorisation.
3 months ago
BioNTech and Autolus enter CAR-T cell therapy collaboration worth over $250m
PMLiVE
BioNTech has announced that it has entered into a strategic collaboration worth over $250m with Autolus Therapeutics to advance both...
2 months ago
Autolus reports data from trial of TRBC1-targeting cell therapy
Clinical Trials Arena
Autolus Therapeutics has reported positive results from the Phase I/II LibrA T1 study of AUTO4, a TRBC1-targeting CAR T cell therapy,...
10 months ago
Autolus Therapeutics plc's (NASDAQ:AUTL) institutional investors lost 8.1% last week but have benefitted from longer ...
Yahoo Finance UK
Key Insights Significantly high institutional ownership implies Autolus Therapeutics' stock price is sensitive to their...
2 months ago
BioNTech adds CAR-T manufacturing with $250m Autolus deal
Pharmaphorum
BioNTech has taken a $200 million stake in Autolus in a private placement that will allow it to tap into the UK company's manufacturing...
3 months ago